CHU Charleroi Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Charleroi Belgium (1996)

Organization Overview

First Clinical Trial
2000
NCT00356226
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Centre Hospitalier Universitaire de Charleroi | Centre Universitaire de Charleroi | CHU Charleroi | CHU de Charleroi | CHU de Charleroi, Belgium | GHdC | Grand Hôpital de Charleroi | Hospital of Charleroi (GHdC), Belgium | ISPPC CHU de Charleroi | Sarah Saxena

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 4)

Beriberi (Phase 4)

Breast Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Hyperlactatemia (Phase 4)

Rectal Neoplasms (Phase 2)

Thiamine Deficiency (Phase 4)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 17